Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Work In Process (2023 - 2025)

Iovance Biotherapeutics has reported Work In Process over the past 3 years, most recently at $12.1 million for Q1 2025.

  • Quarterly results put Work In Process at $12.1 million for Q1 2025, up 104.4% from a year ago — trailing twelve months through Mar 2025 was $12.1 million (up 104.4% YoY), and the annual figure for FY2024 was $8.8 million, up 52.46%.
  • Work In Process for Q1 2025 was $12.1 million at Iovance Biotherapeutics, up from $8.8 million in the prior quarter.
  • Over the last five years, Work In Process for IOVA hit a ceiling of $12.1 million in Q1 2025 and a floor of $4.3 million in Q3 2023.
  • Median Work In Process over the past 3 years was $7.3 million (2023), compared with a mean of $7.6 million.
  • Biggest five-year swings in Work In Process: surged 52.46% in 2024 and later skyrocketed 104.4% in 2025.
  • Iovance Biotherapeutics' Work In Process stood at $5.7 million in 2023, then surged by 52.46% to $8.8 million in 2024, then skyrocketed by 37.91% to $12.1 million in 2025.
  • The last three reported values for Work In Process were $12.1 million (Q1 2025), $8.8 million (Q4 2024), and $5.9 million (Q1 2024) per Business Quant data.